Human Rabies Vaccine With Vero Cell Culture Technology

As a trusted global supplier of high-quality biological products, AIM Honor (Ningbo) Biopharmaceutical Co., Ltd. offers the Human Rabies Vaccine With Vero Cell Culture Technology to healthcare systems and government procurement agencies worldwide. This lyophilized rabies vaccine is manufactured under stringent GMP conditions in B+A grade cleanroom environments, utilizing advanced Vero cell culture technology and multi-step chromatographic purification to achieve exceptional antigen purity and immunogenic potency. Each vial undergoes rigorous quality control testing exceeding national pharmacopoeia standards, guaranteeing consistent safety and efficacy. Indicated for both pre-exposure prophylaxis in high-risk occupational groups and post-exposure management following suspected rabid animal contact, this preparation serves as a critical intervention in global rabies elimination strategies and emergency outbreak response.

Product Characteristics

The Human Rabies Vaccine With Vero Cell Culture Technology is a freeze-dried preparation of rabies fixed virus propagated in Vero cells, designed to deliver consistent immunogenic response across all indicated populations. After cultivation and harvest, the virus suspension undergoes inactivation, concentration, and purification, followed by lyophilization with stabilizers to ensure long-term antigen stability. The reconstituted vaccine presents as a clear, colorless liquid free from visible particulates. Below is the comprehensive product specification table detailing the composition and physical characteristics of this advanced biological preparation.

In summary, this lyophilized formulation ensures convenient storage and reliable immunogenicity, making it suitable for both routine immunization programs and emergency stockpiling in diverse healthcare settings.

Core Advantages

As a leading China-based manufacturer, AIM Honor has engineered the Human Rabies Vaccine With Vero Cell Culture Technology to deliver superior protection through multiple technological and quality advantages that distinguish it in the global vaccine marketplace. The following points outline the key strengths that make this preparation a preferred choice for national immunization programs and institutional procurement.

1. High-Titer Antigen Production: The aGV strain demonstrates exceptional replication efficiency in Vero cell culture, yielding high-titer virus harvests that translate to potent immunogenicity exceeding 2.5 IU per dose after purification.

2. Rapid Seroconversion: Clinical data confirm a 100% antibody seroconversion rate within 14 days of completing the standard immunization schedule, providing timely protection when it matters most.

3. Advanced Purification Technology: Multi-step purification employing 20m² ultrafiltration systems and 600mm chromatography columns effectively removes foreign proteins, residual DNA, and process-related impurities, achieving antigen purity that meets stringent international standards.

4. Preservative-Free Formulation: The vaccine contains no preservatives or antibiotics, significantly reducing the risk of hypersensitivity reactions and making it suitable for sensitive populations including children and the elderly.

5. Proven Stability Profile: Lyophilization performed in a 40m² freeze-drying system under strictly controlled parameters ensures a 36-month shelf life with maintained antigen activity, facilitating long-term stockpiling and international cold chain logistics.

6. Rigorous Quality Control: Internal control standards surpass national pharmacopoeia requirements, including endotoxin limits ≤10EU per dose, mandatory sterility testing, and precise pH monitoring throughout production.

These integrated technological and quality advantages establish this vaccine as a frontline defense in global rabies control efforts, offering healthcare providers a reliable and efficient immunization tool.

Indicated Populations

The broad indication profile of this Vero cell-derived rabies vaccine makes it suitable for diverse demographic groups requiring protection against rabies virus exposure. Understanding the appropriate target populations is essential for procurement planning and immunization program design.

1. Post-Exposure Prophylaxis Recipients: Any individual bitten or scratched by a suspected rabid animal, regardless of age or sex, should receive immediate wound cleansing followed by vaccine administration according to the post-exposure schedule. This includes cases involving dogs, cats, bats, and other mammals capable of transmitting the rabies virus.

2. Pre-Exposure Prophylaxis Candidates: High-risk occupational groups require preventive immunization, including veterinarians, animal handlers, forestry workers, slaughterhouse personnel, rabies laboratory staff, and wildlife conservation workers who have regular contact with potentially infected animals.

3. Pediatric and Geriatric Populations: Children exposed to animal bites receive the same dosing schedule as adults, with intramuscular injection administered in the anterolateral aspect of the thigh for young children. Elderly patients with potential immunosenescence may benefit from doubled first-dose administration under specific clinical circumstances.

4. Immunocompromised Individuals: Patients with congenital or acquired immunodeficiency conditions receiving post-exposure prophylaxis may require adjusted dosing protocols, including doubled initial vaccine doses, to ensure adequate protective antibody responses.

5. International Travelers: Individuals traveling to rabies-endemic regions where access to post-exposure prophylaxis may be limited should consider pre-exposure vaccination as a preventive measure.

In conclusion, the Human Rabies Vaccine With Vero Cell Culture Technology provides a versatile prophylaxis solution for individuals across all risk categories, from occupational exposure to travel-related risks, making it an essential component of any comprehensive rabies prevention strategy.

Immunization Schedule

Proper administration technique and adherence to recommended immunization schedules are critical for achieving optimal protective efficacy. The following protocols outline the standardized procedures for reconstitution, injection, and dosing schedules that healthcare providers should follow when administering this lyophilized rabies vaccine.

1. Reconstitution Procedure: Reconstitute the freeze-dried vaccine cake with the enclosed sterile water for injection according to the stated volume on the vial label. Shake the container thoroughly until complete dissolution yields a clear, particle-free liquid ready for immediate administration.

2. Route of Administration: The vaccine is administered exclusively via intramuscular injection in the deltoid muscle of the upper arm for adults and older children. For young children, the injection site should be the anterolateral aspect of the thigh muscle to ensure proper absorption and minimize discomfort.

3. Standard Post-Exposure Schedule: One dose is administered on days 0 (the day of first presentation), 3, 7, 14, and 28, totaling five doses. This Essen regimen provides the established framework for inducing protective immunity following suspected rabies exposure.

4. Pre-Exposure Schedule: Three doses administered on days 0, 7, and 21 or 28 provide baseline immunity for individuals at occupational risk. Booster doses may be recommended based on ongoing exposure risk assessment and serological monitoring.

5. Special Dosing Considerations: The first vaccine dose should be doubled in cases involving chronic disease patients receiving rabies immunoglobulin concurrently, individuals with immunodeficiency conditions, patients on immunosuppressive therapy, elderly recipients, or when vaccination initiation is delayed beyond 48 hours post-exposure.

Proper implementation of these protocols ensures optimal seroconversion and long-term protection against rabies, supporting successful patient outcomes in both routine and emergency settings.

Quality Assurance

AIM Honor (Ningbo) Biopharmaceutical Co., Ltd. maintains an uncompromising commitment to quality across every stage of the Human Rabies Vaccine With Vero Cell Culture Technology production cycle. Our comprehensive quality assurance framework integrates international GMP standards, advanced facility infrastructure, and rigorous testing protocols to deliver products that consistently meet global regulatory expectations.

1. GMP-Certified Manufacturing: All production activities occur within B+A grade cleanroom environments, with personnel wearing fully enclosed protective equipment during sterile operations including strain passage, cell expansion, and formulation processes.

2. Closed Sterile Systems: Bacterial culture and virus propagation are completed in fully closed sterile operation systems, eliminating external contamination risks and maintaining the integrity of the biological manufacturing chain from master cell bank to final product.

3. Multi-Step Quality Testing: Each batch undergoes comprehensive testing including potency assays, sterility verification, endotoxin quantification (≤10EU/dose), pH analysis, and stability monitoring throughout the assigned shelf life.

4. Domestically Developed aGV Strain: The highly effective aGV rabies virus strain, developed through domestic research and characterization, demonstrates consistent growth properties and antigenic stability, ensuring reliable batch-to-batch consistency.

5. International Pharmacopoeia Compliance: Quality specifications align with or exceed requirements established by major pharmacopoeias, facilitating product registration and market authorization across diverse regulatory jurisdictions.

This robust quality infrastructure guarantees that every vial meets the highest standards of purity, potency, and safety, providing healthcare providers with absolute confidence in product reliability.

Frequently Asked Questions

Q: What is the recommended storage condition for this lyophilized rabies vaccine?

A: The vaccine must be stored and transported between +2°C and +8°C, protected from light at all times. Maintaining this cold chain temperature range is essential for preserving antigen integrity and ensuring the full 36-month shelf life. Freezing should be avoided as it may compromise the lyophilized cake structure and reconstitution characteristics. Upon reconstitution with the provided sterile water for injection, the vaccine should be administered immediately and not stored for later use.

Q: How should wound management be performed before vaccine administration?

A: Immediate and thorough wound cleansing is the critical first step in post-exposure management. The wound should be flushed repeatedly with clean water or soap water for a minimum of 15 minutes, followed by application of iodine tincture or ethanol for disinfection. This mechanical removal of virus particles from the exposure site significantly reduces the viral load and complements the immunoprotection provided by subsequent vaccination. Wound suturing should be delayed unless absolutely necessary for hemostasis.

Q: What are the common adverse reactions after vaccination?

A: The most frequently observed local reactions include redness, swelling, pain, and itching at the injection site, which typically appear within 24 hours and resolve spontaneously without specific treatment. Systemic reactions may include low-grade fever, malaise, headache, dizziness, arthralgia, myalgia, vomiting, and abdominal discomfort, all of which are generally mild and self-limiting. Rare adverse events requiring medical attention include moderate to high fever needing antipyretic therapy, urticaria occurring within 72 hours, and extremely rare anaphylactic reactions that necessitate immediate emergency intervention with adrenaline.

Q: Are there any contraindications for post-exposure vaccination?

A: Because rabies is uniformly fatal once clinical symptoms manifest, there are absolutely no contraindications for post-exposure immunization. The vaccine must be administered regardless of pregnancy, infancy, advanced age, concurrent illness, or known allergies to vaccine components. For pre-exposure prophylaxis, contraindications include known hypersensitivity to any vaccine component, acute febrile illness, severe chronic diseases in acute exacerbation, uncontrolled epilepsy, and progressive neurological disorders. In such cases, the risk-benefit assessment should guide clinical decision-making.

Q: What is the re-immunization protocol for previously vaccinated individuals?

A: Re-immunization recommendations depend on the time elapsed since the last complete vaccination series. Individuals who completed the full immunization schedule within the past year should receive one dose each on days 0 and 3 if re-exposed. Those whose complete immunization occurred more than one year ago should undergo the full five-dose post-exposure schedule. For recipients who completed primary immunization within three years and received booster doses, two doses on days 0 and 3 suffice. When complete immunization and boosters were administered more than three years ago, a complete post-exposure series is indicated.

Q: Does the manufacturer support bulk procurement and international shipping?

A: Yes, AIM Honor (Ningbo) Biopharmaceutical Co., Ltd. is fully equipped to handle bulk purchasing orders and cross-border supply arrangements. Our logistics infrastructure supports temperature-controlled international shipping with validated cold chain packaging solutions that maintain the required +2°C to +8°C range throughout transit. We provide comprehensive documentation packages including certificates of analysis, GMP certificates, and regulatory dossiers to facilitate customs clearance and import procedures. Direct factory procurement ensures competitive pricing and stable supply continuity for government tenders, institutional buyers, and international health organizations.

Why Partner With Us

Partnering with AIM Honor for the Human Rabies Vaccine With Vero Cell Culture Technology means choosing a manufacturer with proven technical expertise, robust production capacity, and an unwavering commitment to global public health. Our modern production facility integrates advanced purification systems, standardized lyophilization platforms, and comprehensive quality management frameworks to deliver vaccines that meet the highest international standards. The following key differentiators illustrate the value we bring to every procurement partnership.

1. Proven Manufacturing Expertise: With a demonstrated 100% antibody seroconversion rate and preservative-free formulation, our vaccine delivers consistent clinical performance backed by rigorous batch-to-batch quality control.

2. Comprehensive Regulatory Support: We provide full documentation packages including certificates of analysis, GMP certifications, and regulatory dossiers tailored to meet the import requirements of diverse national health authorities.

3. Global Logistics Capability: Our validated cold chain shipping solutions ensure product integrity from factory to final destination, with temperature monitoring throughout transit to maintain the required +2°C to +8°C range.

4. Dedicated Account Management: Each procurement partner receives personalized support from inquiry through delivery, including technical consultation, sample evaluation coordination, and after-sales assistance.

5. Scalable Supply Capacity: Our modern manufacturing facility is equipped to handle bulk orders for national immunization programs, institutional tenders, and emergency outbreak response with reliable lead times.

We invite you to contact our team to discuss procurement requirements and experience the AIM Honor commitment to excellence in vaccine manufacturing and supply.